ChemoID assay for glioblastoma.

e13028 Background: Glioblastoma multiforme (GBMs) are brain tumors with low survival rates due to the presence of chemoresistant Glioma Cancer Stem-Like Cells (GCSLCs). Development of a test that identifies the most effective chemotherapy management for GCSLCs offers great promise for personalized anticancer treatments. Methods: We have developed a drug response assay (ChemoID) designed to predict the response of GCSLCs and bulk of tumor cells of a given patient by measuring cell death following chemotherapy treatments at clinically relevant doses. In a blinded study of 11 patients affected by Glioblastoma Grade IV we assessed the accuracy of the ChemoID assay by comparing the test results to clinical response. Tumors were classified as responsive (60-100% cell kill), intermediate (30-60% cell kill), and non-responsive (0-30% cell kill) to chemotherapy. Treatment was blinded to assay results. MRI and CT scan determined response to therapy. The effectiveness of the ChemoID predicted drugs and clinical resp...